MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Oramed Pharmaceuticals ROCE Ratio 2011-2025 | ORMP
Annual ROCE Ratio Oramed Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.37 | -25.93 | -14.22 | -29.32 | -49.84 | -31.57 | -32.11 | -25.53 | -29.69 | -28.35 | -52.73 | -62.02 | -62.69 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.37 | -62.69 | -34.88 |
Quarterly ROCE Ratio Oramed Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.77 | -8.58 | -8.75 | -5.41 | -7.31 | -7.27 | -7.97 | -7.7 | -12.89 | -16.18 | -21.06 | -19.29 | -26.53 | -27.2 | -24.49 | -22.34 | -36.56 | -52.51 | -53.56 | -65.38 | -53.08 | -73.14 | -82.5 | -75.01 | -77.61 | -59.98 | -55.53 | -58.0 | -53.74 | -53.12 | -48.96 | -44.9 | -43.37 | -3.26 | 8.55 | 22.04 | 38.85 | 1.39 | -10.56 | -26.53 | -45.39 | -4.0 | 11.71 | 12.43 | 4.52 | -56.67 | -82.16 | -87.34 | -82.7 | -83.8 | -79.07 | -80.49 | -82.61 | -88.14 | -91.74 | -88.0 | -47.39 | -15.23 | -11.99 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.85 | -91.74 | -37.04 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.93 | 4.78 % | $ 818 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-91.24 | $ 3.2 | -1.69 % | $ 247 M |  USA |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
-517.39 | $ 1.07 | -5.75 % | $ 295 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 213.33 | -3.22 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.13 | -4.96 % | $ 7.53 B |  Australia |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
BioVie
BIVI
|
-95.03 | $ 1.42 | -1.85 % | $ 2.1 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-353.66 | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
-4.81 | $ 93.93 | -0.93 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-40.28 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
28.05 | $ 26.45 | 4.67 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 9.6 | 0.37 % | $ 141 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 0.26 | -6.98 % | $ 566 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
424.75 | $ 12.98 | -7.91 % | $ 854 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-531.85 | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
2.51 | $ 548.58 | -2.78 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.37 | 2.83 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | $ 91.59 | 1.95 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-26.11 | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 8.97 | -0.44 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-15.33 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
95.22 | $ 11.33 | -1.78 % | $ 733 M | USA |
 |
Biogen
BIIB
|
31.45 | $ 175.2 | 0.63 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
-317.92 | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
20.15 | $ 87.67 | -0.36 % | $ 9.05 B | USA |
 |
ADiTx Therapeutics
ADTX
|
-5611.16 | $ 1.43 | -36.18 % | $ 18.8 K | USA |
 |
Cellectar Biosciences
CLRB
|
257.01 | $ 3.28 | -9.39 % | $ 40.1 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1339.01 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
26.82 | $ 24.29 | 2.84 % | $ 2.88 B | USA |